Home/ Stocks/ SYRE

Spyre Therapeutics, Inc. Common Stock

SYRE XNAS

$104.91 +1.49 (+1.44%) ▲ 15-min delayed

Open

$106.01

High

$106.67

Low

$103.64

Volume

526.6K

Market Cap

$9.12B

About Spyre Therapeutics, Inc. Common Stock

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 112 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-36,200,000	N/A
Q1 2026	$0	$-69,005,000	N/A
FY 2025	$0	$-155,203,000	N/A
Q3 2025	$0	$-11,183,000	N/A

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for SYRE yet. Check out our latest market news or earnings calendar.

Get SYRE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Spyre Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.